Anavex Life Sciences Corp (AVXL)

[crescentmotor]

I do see the bigger picture as reflected in my some 35% chance of approval.

Sure--can't wait for your big picture view if AVXL reaches Stop Clock 2. You might even be up to 45% and not a single thing will have changed about the clinical trial (which you claim is the deal breaker that will result in lack of Blarcamesine approval in Europe)--including the number of patients, the length of the trial, the title given to the trial, the meeting of the endpoints or lack thereof--NOTHING!